Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Annales de Pathologie
- Vol. 41 (6) , 507-520
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical managementCancer Genetics, 2013
- Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)Laboratory Investigation, 2012
- Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breastHistopathology, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancerBreast Cancer Research and Treatment, 2011
- Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerBritish Journal of Cancer, 2010
- HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab TrialJournal of Clinical Oncology, 2010
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingVirchows Archiv, 2010
- Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)Annals of Oncology, 2009
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989